<DOC>
	<DOCNO>NCT00022477</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness BMS-247550 treating patient recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>BMS-247550 Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient locally recurrent metastatic colorectal cancer treat BMS-247550 . - Determine toxicity drug patient . - Determine duration response , median overall survival , time progression patient treat drug . OUTLINE : This multicenter study . Patients receive BMS-247550 IV 3 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 6 week . PROJECTED ACCRUAL : A total 21-50 patient accrue study within 8-10 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic locally recurrent adenocarcinoma colon rectum amenable potentially curative surgical resection At least 1 unidimensionally measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan The following consider measurable lesion : Lesions see colonoscopic examination barium study Bone metastases CNS lesion Ascites Failed prior combination therapy comprise fluorouracil , leucovorin calcium , irinotecan metastatic disease No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL ALT/AST great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No grade 2 great peripheral neuropathy No history allergic hypersensitivity reaction compound contain polyoxyethylated castor oil ( Cremophor EL ) ( e.g. , paclitaxel compound similar chemical biological composition BMS247550 ) No currently active malignancy ( le 30 % risk relapse complete prior therapy ) except nonmelanoma skin cancer carcinoma situ cervix No uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent colonystimulating factor first course therapy Chemotherapy : See Disease Characteristics Prior adjuvant chemotherapy allow At least 4 week since prior cytotoxic chemotherapy recover No 1 prior chemotherapy regimen metastatic disease No concurrent chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent therapeutic radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery Other : At least 30 day since prior investigational agent At least 7 day since prior cimetidine No concurrent anticancer investigational agent , commercial agent , therapies No concurrent unconventional therapy , food , vitamin supplement contain Hypericum perforatum ( St. John 's Wort ) No concurrent cimetidine No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>